Immune therapy developed through Sanford Burnham Prebys and Lilly collaboration enters Phase 1 clinical trial

Sanford Burnham Prebys Medical Discovery Institute (SBP) today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating LY3361237, a biologic that inhibits inflammation by activating an immune checkpoint receptor.